Androgen receptor gene mutation, rearrangement, polymorphism.

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Androgen receptor (AR) genetic aberrations, including mutations and rearrangements, lead to altered receptor function compared to wild-type AR.
• Over 1,000 AR mutations are documented, primarily linked to androgen insensitivity syndrome (AIS).
• AR mutations are less common in early-stage prostate cancer but increase in castration-resistant prostate cancer (CRPC) patients (10-30%) undergoing anti-androgen therapy.

Purpose of the Study:

• To investigate novel androgen receptor (AR) mutations emerging in response to anti-androgen therapies.
• To understand the role of AR mutations in the development of resistance to small molecule pharmacological agents in CRPC.

Main Methods:

• Literature review of reported AR mutations in prostate cancer and AIS.
• Analysis of mutation data in the context of anti-androgen treatment resistance.
• Focus on gain-of-function mutations within the ligand-binding domain (LBD) of the AR.

Main Results:

• Gain-of-function mutations in the AR's LBD are a key mechanism for resistance to anti-androgens like bicalutamide and enzalutamide.
• Specific AR mutations confer resistance by altering receptor activity and signaling pathways.

Conclusions:

• Understanding AR mutation mechanisms is essential for overcoming therapeutic resistance in CRPC.
• Further research into AR mutations driven by drug resistance is critical for advancing prostate cancer treatment strategies.